Correction: Oncogenic RAS-induced senescence in human primary thyrocytes: molecular effectors and inflammatory secretome involved
Metrics: PDF 403 views | ?
1Molecular Mechanism Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
2Cell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK
3Laboratory of Molecular Pathology, Department of Pathology, IRCCS Foundation - Istituto Nazionale dei Tumori, Milan, Italy
4Scientific Directorate, IRCCS Foundation - Istituto Nazionale dei Tumori, Milan, Italy
Published: October 14, 2022
Copyright: © 2022 Vizioli et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This article has been corrected: Due to errors during figure assembly, an incorrect blot was used for the p53 panel in Figure 3G. Additionally, the actin panel of Figure 1D is an accidental duplicate of the actin panel in Figure 2H. The corrected Figure 3G and 1D are shown below. The authors declare that these corrections do not change the results or conclusions of this paper.
Original article: Oncotarget. 2014; 5:8270–8283. DOI: https://doi.org/10.18632/oncotarget.2013
Figure 1: Oncogenic RAS triggers senescence in human primary thyrocytes. (D) Determination by western blotting of protein levels as indicated in an independent experiment; β-actin serves as loading control. The molecular weight of each protein is indicated. Data are from a representative out of two independent experiments.
Figure 3: Effect of p53 knockdown on RAS-induced senescence in primary thyrocytes. (G) Western blotting analysis for the expression of the indicated proteins performed in an independent experiment; β-actin was used as loading control; the molecular weight of each protein is shown. shp53: short hairpin targeting p53; CV: crystal violet ; IF: immunofluorescence.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.